Tirzepatide vs Mazdutide
Both are dual agonists, but they pair GLP-1 with a different second receptor. Tirzepatide pairs it with GIP; mazdutide pairs it with glucagon. The second receptor is what sets their research profiles apart.
| Tirzepatide | Mazdutide | |
|---|---|---|
| Compound class | Dual GIP/GLP-1 receptor agonist | Dual GLP-1/glucagon receptor agonist |
| Primary target | GIP + GLP-1 receptors | GLP-1 + glucagon receptors |
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Administration | Weekly subcutaneous | Weekly subcutaneous |
| Research focus | Body-composition & glycemic endpoints | Weight & hepatic metabolic endpoints |
Key differences
- Second receptor: tirzepatide = GIP + GLP-1; mazdutide = glucagon + GLP-1.
- Glucagon angle: mazdutide's glucagon component is studied for energy expenditure and hepatic endpoints, similar in spirit to retatrutide's third arm.
- Dataset: tirzepatide is more broadly characterized; mazdutide is an emerging dual agonist with a growing research base.
- Both are weekly subcutaneous, milligram-dosed, slowly titrated compounds.
Which is right for your research?
Pick tirzepatide for GIP-based dual-incretin research and mazdutide when the glucagon pathway is the variable of interest.
Frequently asked questions
Are tirzepatide and mazdutide both dual agonists?
Yes, but on different receptors. Tirzepatide activates GIP and GLP-1; mazdutide activates glucagon and GLP-1.
What does mazdutide's glucagon activity add?
Glucagon-receptor agonism is studied for effects on energy expenditure and hepatic metabolism, a mechanism tirzepatide does not have.
How are they dosed?
Both are weekly subcutaneous research compounds dosed in milligrams and titrated upward.
For Research Use Only. All products are sold as research chemicals for in-vitro laboratory study. Not for human consumption, medical, veterinary, or household use.